![SonomaEye-full-color-vector[2].png](https://static.wixstatic.com/media/bed00b_da20b9cc704044b0b048ac8ef9190470~mv2_d_3024_2195_s_2.png/v1/fill/w_177,h_123,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/SonomaEye-full-color-vector%5B2%5D.png)
Thank you for your submission!
Interventional retrospective case series of patients undergoing treatment intervals of more than twenty-four (24) weeks with faricimab
Adrian Babel
Presenter:
Adrian Babel MS1,4, Eric K. Chin MD2,3 & David Almeida, MD MBA PhD4
Authors:
Affiliation:
1. Boonshoft School of Medicine, Dayton, OH, USA
2. Retina Consultants of Southern California, Redlands, CA, USA
3. Loma Linda Eye Institute; Veterans Affair Hospital, Loma Linda, CA, USA
4. Erie Retina Research & Center for Advanced Surgical Exploration, Erie, PA, USA
Purpose: To evaluate the efficacy of intravitreal faricimab dosing interval at and beyond twenty-four (24) weeks in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
Methods: Retrospective case series of six (6) patients with persistent DME and nAMD who received intravitreal faricimab at and beyond the 24-week (six-month) dosing interval regimen.
Results: The majority of patients experienced improved vision (mean best-corrected visual acuity (BCVA) improvement of 10.5 letters) and anatomy (mean central macular thickness (CMT) decrease of 37.667μm on optical coherence tomography (OCT)) at 6 months despite extended faricimab dosing intervals.
Conclusions: Extended intravitreal faricimab dosing intervals at and beyond 24 weeks maintained visual and anatomical outcomes in patients over 6 months. This suggests the feasibility of personalized extended dosing tailored to each patient’s disease activity, potentially reducing treatment burden.